In The Field - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

In The Field

Pharmaceutical Technology



Company Notes
For those reasons, an FOBs regime would create a "patent protection gap" that would allow a follow-on manufacturer to elude an innovator's patents while still relying on the innovator's product to bypass the full regulatory process.

Greenwood remarked that a 14-year exclusivity period for biologics would be consistent with previous Congressional efforts to protect the pharmaceutical industry. "Given that Congress has previously concluded that up to 14 years of patent protection is appropriate for drugs and biologic products, any statutory formula that allows for follow-on biologics should allow for at least the same degree of effective market protection," Greenwood said in a prepared statement.

Data exclusivity is particularly important for the biotechnology industry, BIO observes, because the industry is composed mainly of small companies with unstable funding. The organization notes that these companies would be vulnerable to follow-on biologics legislation that could change investment incentives.
-Erik Greb

REGULATION

FDA Issues Guidance for Testing for DEG-Contaminated Glycerin

Rockville, MD (May 1)—The US Food and Drug Administration ( http://www.fda.gov/) issued a guidance to alert pharmaceutical manufacturers, pharmacy compounders, repackers, and suppliers to the potential public health hazard of glycerin contaminated with diethylene glycol (DEG), a poison.

FDA has received and continues to receive (most recently in October 2006) reports about fatal DEG poisoning of consumers who ingested medicinal syrups such as cough syrup or acetaminophen syrup that were manufactured with DEG-contaminated glycerin. The guidance provides recommendations to help pharmaceutical manufacturers, repackers, other suppliers of glycerin, and pharmacists who engage in drug compounding avoid using glycerin that is contaminated with DEG and prevent incidents of DEG poisoning.

To avoid using DEG-contaminated glycerin, FDA advises that certain analytical testing procedures be performed on all lots of glycerin. These tests include a specific identity test that incorporates a limit test for DEG on all containers of all lots of glycerin before the glycerin is used in the manufacture or preparation of drug products.


Company Notes
The relevant safety limit for DEG is 0.1%, as recognized by the United States Pharmacopeia (USP) monograph for glycerin.

FDA recommends that a manufacturer perform the identity tests, including the limit test for DEG, which appears in the USP monograph for glycerin. Alternatively, a manufacturer may use an equivalent identification procedure that includes a test to detect and quantify DEG, provided it meets the relevant safety limit. One alternative procedure is a thin-layer chromatography method published in the Journal of AOAC International.

FDA also advises that drug-product manufacturers know their supply chain for glycerin, including the manufacturer of the component and any subsequent distributors. The agency advises that all personnel in pharmaceutical manufacturing facilities, especially personnel directly responsible for the receipt, testing, and release of glycerin, should be made aware of the importance of proper testing and the potential hazards if the testing is not done.

The guidance further urges repackers and others who distribute and prepare glycerin for use in drug products to test glycerin that is used, sold for use, or intended for use in drug products. FDA also recommends that pharmacies that use glycerin in compounding drug products either test the glycerin for DEG content or ensure that such testing was properly done by a reliable supplier. In addition, FDA says that bulk or repackaged glycerin intended for use as an excipient or other component of a drug product should be tested for DEG content following good manufacturing practices.
-Patricia Van Arnum


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
29%
Attracting a skilled workforce
27%
Obtaining/maintaining adequate financing
13%
Regulatory compliance
31%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Source: Pharmaceutical Technology,
Click here